Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver

BACKGROUND AND OBJECTIVE: For patients with metastatic non-small cell lung cancer (NSCLC) without an oncogenic driver, systemic therapy with immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy have significantly improved the outcomes. However, the majority of patients do no...

Descripción completa

Detalles Bibliográficos
Autor principal: Stinchcombe, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903081/
https://www.ncbi.nlm.nih.gov/pubmed/36762068
http://dx.doi.org/10.21037/tlcr-22-530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903081/
https://www.ncbi.nlm.nih.gov/pubmed/36762068
http://dx.doi.org/10.21037/tlcr-22-530

Ejemplares similares